Last $2.81 USD
Change Today +0.125 / 4.66%
Volume 42.3K
As of 5:20 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

vermillion inc (VRML) Snapshot

Open
$2.71
Previous Close
$2.69
Day High
$2.85
Day Low
$2.66
52 Week High
05/31/13 - $4.07
52 Week Low
04/16/13 - $1.06
Market Cap
100.7M
Average Volume 10 Days
44.5K
EPS TTM
$-0.45
Shares Outstanding
35.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERMILLION INC (VRML)

Related News

No related news articles were found.

vermillion inc (VRML) Related Businessweek News

No Related Businessweek News Found

vermillion inc (VRML) Details

Vermillion, Inc., together with its subsidiaries, is engaged in the discovery, development, and commercialization of diagnostic tests that help physicians diagnose, treat, and enhance outcomes for patients. It develops diagnostic tests in the fields of oncology and women’s health. The company’s lead product is OVA1, an ovarian cancer blood test for pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices. The company was founded in 1993 and is headquartered in Austin, Texas.

26 Employees
Last Reported Date: 03/31/14
Founded in 1993

vermillion inc (VRML) Top Compensated Officers

Chief Scientific Officer, Senior Vice Preside...
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2012.

vermillion inc (VRML) Key Developments

Vermillion, Inc. to Open Clinical Reference Laboratory, ASPiRA LABS, in Austin, Texas

Vermillion, Inc. has obtained certain permits and has completed certain other regulatory processes necessary to open a clinical reference laboratory, ASPiRA LABS, in Austin, Texas. The laboratory will offer tests related to gynecologic oncology and women’s health including Vermillion’s OVA1 ovarian cancer test.

Vermillion, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2013

Vermillion, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2013. For the quarter, the company reported net loss of $1,817,000 or $0.07 basic and diluted loss per share on total revenue of $1,585,000 against net loss of $1,375,000 or $0.09 basic and diluted loss per share on total revenue of $1,142,000 a year ago. Loss from operations was $1,825,000 and loss before income taxes was $1,817,000 against loss from operations of $1,281,000 and loss before income taxes of $1,375,000 a year ago. For the year, the company reported net loss of $8,819,000 or $0.42 basic and diluted loss per share on total revenue of $2,566,000 against net loss of $7,146,000 or $0.48 basic and diluted loss per share on total revenue of $2,094,000 a year ago. Loss from operations was $8,863,000 and loss before income taxes was $8,819,000 against loss from operations of $9,414,000 and loss before income taxes of $7,146,000 a year ago.

Vermillion, Inc. to Report Q4, 2013 Results on Mar 06, 2014

Vermillion, Inc. announced that they will report Q4, 2013 results at 9:01 PM, GMT Standard Time on Mar 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRML:US $2.81 USD +0.125

VRML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arrayit Corp $0.14 USD +0.0049
Health Discovery Corp $0.03 USD 0.00
Imperial Innovations Group PLC 452.50 GBp +15.00
MDxHealth €4.30 EUR +0.311
Miraculins Inc C$0.23 CAD +0.005
View Industry Companies
 

Industry Analysis

VRML

Industry Average

Valuation VRML Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.4x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.6x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERMILLION INC, please visit www.vermillion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.